Sarcopenia is associated with worse overall survival in patients with anal squamous cell cancer

2020 ◽  
Vol 121 (7) ◽  
pp. 1148-1153 ◽  
Author(s):  
Katherine Bingmer ◽  
Victor Kondray ◽  
Asya Ofshteyn ◽  
Jonathan T. Bliggenstorfer ◽  
David W. Dietz ◽  
...  
Keyword(s):  
Overall Survival ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Anal Squamous Cell Cancer

scholarly journals Low cardiac dose and neutrophil-to-lymphocyte ratio predict overall survival in inoperable esophageal squamous cell cancer patients after chemoradiotherapy

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yu-Chieh Ho ◽  
Yuan-Chun Lai ◽  
Hsuan-Yu Lin ◽  
Ming-Hui Ko ◽  
Sheng-Hung Wang ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Performance Status ◽  
Cell Cancer ◽  
Esophageal Squamous Cell Cancer ◽  
Lymphocyte Ratio ◽  
Cardiac Dose

AbstractWe aimed to determine the prognostic significance of cardiac dose and hematological immunity parameters in esophageal cancer patients after concurrent chemoradiotherapy (CCRT). During 2010–2015, we identified 101 newly diagnosed esophageal squamous cell cancer patients who had completed definitive CCRT. Patients' clinical, dosimetric, and hematological data, including absolute neutrophil count, absolute lymphocyte count, and neutrophil-to-lymphocyte ratio (NLR), at baseline, during, and post-CCRT were analyzed. Cox proportional hazards were calculated to identify potential risk factors for overall survival (OS). Median OS was 13 months (95% confidence interval [CI]: 10.38–15.63). Univariate analysis revealed that male sex, poor performance status, advanced nodal stage, higher percentage of heart receiving 10 Gy (heart V10), and higher NLR (baseline and follow-up) were significantly associated with worse OS. In multivariate analysis, performance status (ECOG 0 & 1 vs. 2; hazard ratio [HR] 3.12, 95% CI 1.30–7.48), heart V10 (> 84% vs. ≤ 84%; HR 2.24, 95% CI 1.26–3.95), baseline NLR (> 3.56 vs. ≤ 3.56; HR 2.36, 95% CI 1.39–4.00), and follow-up NLR (> 7.4 vs. ≤ 7.4; HR 1.95, 95% CI 1.12–3.41) correlated with worse OS. Volume of low cardiac dose and NLR (baseline and follow-up) were associated with worse patient survival.

scholarly journals FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer

2019 ◽  
Vol 18 (1) ◽  
pp. e39-e52 ◽  
Author(s):  
Sebastian Mondaca ◽  
Walid K. Chatila ◽  
David Bates ◽  
Jaclyn F. Hechtman ◽  
Andrea Cercek ◽  
...  
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Anal Squamous Cell Cancer

Refusal of Chemoradiation Therapy for Anal Squamous Cell Cancer

2020 ◽  
Vol 24 (9) ◽  
pp. 2140-2142
Author(s):  
Adam C. Fields ◽  
Pamela W. Lu ◽  
Benjamin M. Vierra ◽  
Nelya Melnitchouk
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Chemoradiation Therapy ◽  
Anal Squamous Cell Cancer

scholarly journals Does Endoscopic Ultrasound Improve Detection of Locally Recurrent Anal Squamous-Cell Cancer?

2015 ◽  
Vol 58 (2) ◽  
pp. 193-198 ◽  
Author(s):  
Carrie Y. Peterson ◽  
Martin R. Weiser ◽  
Philip B. Paty ◽  
Jose G. Guillem ◽  
Garrett M. Nash ◽  
...  
Keyword(s):  
Squamous Cell ◽  
Endoscopic Ultrasound ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Locally Recurrent ◽  
Anal Squamous Cell Cancer

Neck Dissection in Relation With Disease-Free, Disease-Specific, and Overall Survival of Patients With Squamous Cell Cancer of the Oral Cavity

2014 ◽  
Vol 25 (6) ◽  
pp. 1992-1997 ◽  
Author(s):  
Georgios Koloutsos ◽  
Konstantinos Vahtsevanos ◽  
Athanassios Kyrgidis ◽  
Nikolaos Kechagias ◽  
Stefanos Triaridis ◽  
...  
Keyword(s):  
Overall Survival ◽  
Oral Cavity ◽  
Neck Dissection ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Disease Free ◽  
Disease Specific

scholarly journals Endoscopic resection with adjuvant treatment versus esophagectomy for early-stage esophageal cancer

2021 ◽  
Author(s):  
Binhao Huang ◽  
Maria Christine Xu ◽  
Arjun Pennathur ◽  
Zhigang Li ◽  
Zhiguo Liu ◽  
...  
Keyword(s):  
Overall Survival ◽  
Esophageal Cancer ◽  
Squamous Cell ◽  
Adjuvant Treatment ◽  
Squamous Cell Cancer ◽  
Early Stage ◽  
Cell Cancer ◽  
Esophageal Squamous Cell Cancer ◽  
R0 Resection ◽  
Muscularis Mucosa

Abstract Objective To evaluate the outcome following the strategy of endoscopic R0 resection (ER) plus adjuvant treatment (AT) versus esophagectomy for esophageal squamous cell cancer in T1a invading muscularis mucosa (M3)-T1b stage. Methods We evaluated the outcomes of 46 esophageal squamous cell cancer (ESCC) patients with T1aM3-T1b stage who underwent ER + AT from the Esophageal Cancer Endoscopic Therapy Consortium (ECETC) and compared these outcomes to 92 patients who underwent esophagectomy. Propensity score matching (1:2) was used, with overall survival (OS) and relapse-free survival (RFS) being compared between the two groups. Results During a median follow-up of 32 months, there were no statistical differences (P = 0.226) in OS between the two groups. The 1-, 2-, and 3-year overall survival in the esophagectomy group was 95%, 91%, and 84%, respectively. There were no mortalities within three years in the ER + AT group. The RFS between the two groups was also not significantly different (P = 0.938). The 1-, 2-, and 3-year RFS of patients in the esophagectomy group was 90%, 90%, and 83%, respectively, while it was 97%, 94%, and 74% in the ER + AT group, respectively. The local recurrence rates between the two groups were not significantly different (P = 0.277). Conclusions This first multicenter analysis showed similar outcomes were found regarding OS and RFS between the two groups in T1aM3-T1b stage patients. ER + AT may be considered in high-risk patients or for those who refuse esophagectomy.

Sign in / Sign up

Export Citation Format

Share Document